CERPASS – A Study of Cemiplimab Given Alone Versus in Combination with the Oncolytic Immunotherapy RP1 to Treat Advanced Cutaneous Squamous Cell Carcinoma

‘*’ – The CERPASS study is currently active but not enrolling.

For more information about the CERPASS study, please see Clinical Trials.gov:

Clinical Trials.gov: https://clinicaltrials.gov/ct2/show/NCT04050436

Identifier: NCT04050436

This is a randomized Phase 2 clinical trial to compare the effects of cemiplimab alone versus a combination of cemiplimab and the investigational oncolytic immunotherapy RP1. Researchers will study the effectiveness of these treatments against tumors and how long the effect lasts for.

RP1 and its use in combination with cemiplimab is investigational, has not been proven to be safe and has not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authority.